Retatrutide Therapy in Miami
Target three metabolic pathways simultaneously with retatrutide — a next-generation triple-agonist peptide activating GLP-1, GIP, and glucagon receptors for the most powerful weight loss results in clinical trials to date, available at Rewind Anti-Aging of Miami.
What Is Retatrutide?
Retatrutide (also known as LY3437943) is a next-generation investigational peptide developed by Eli Lilly for the treatment of obesity and Type 2 diabetes. What sets retatrutide apart from existing weight loss medications is its triple-agonist mechanism — it simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. No other approved or late-stage weight loss compound targets all three of these pathways at once.
In a Phase 2 clinical trial published in the New England Journal of Medicine in 2023, participants receiving retatrutide at the highest dose achieved an average weight loss of 24.2% of their body weight over 48 weeks. This result exceeded outcomes reported for semaglutide (approximately 15-16%) and tirzepatide (approximately 22.5%) in their respective pivotal trials. Retatrutide is currently in Phase 3 clinical trials and is available through compounding pharmacies under medical supervision while it awaits FDA approval.
How Retatrutide Works
Retatrutide activates three distinct metabolic receptors, creating a synergistic effect that addresses weight loss from multiple angles simultaneously.
GLP-1 Receptor Agonism
Reduces appetite, slows gastric emptying, and improves insulin sensitivity. This is the same pathway activated by semaglutide and is the foundation of modern medical weight loss.
GIP Receptor Agonism
Enhances insulin secretion, improves fat metabolism, and works synergistically with GLP-1 signaling. This dual incretin effect is what gives tirzepatide its edge over semaglutide — retatrutide includes it as well.
Glucagon Receptor Agonism
Increases energy expenditure, promotes hepatic fat oxidation, and drives thermogenesis. This is the unique third pathway that distinguishes retatrutide and may explain its superior weight loss results.
Superior Clinical Results
Phase 2 data showed up to 24.2% body weight reduction at 48 weeks — surpassing both semaglutide and tirzepatide. The triple-agonist approach creates a compounding metabolic effect no single or dual-agonist can match.
Metabolic Health Benefits
Beyond weight loss, retatrutide improved glycemic control, reduced liver fat (by up to 81% in trial participants), lowered triglycerides, and improved multiple cardiometabolic markers.
Who Is Retatrutide For?
Retatrutide is designed for individuals seeking significant, medically supervised weight loss who want access to the most advanced peptide therapy available.
BMI 30+ Obesity
Adults with a BMI of 30 or greater who need substantial weight reduction and have not achieved lasting results with diet and exercise alone.
Metabolic Syndrome
Patients with insulin resistance, elevated blood sugar, high triglycerides, or other metabolic markers who need both weight loss and metabolic improvement.
Plateau on Other GLP-1s
Patients who have used semaglutide or tirzepatide and hit a weight loss plateau may benefit from retatrutide's additional glucagon receptor pathway to break through stalls.
Fatty Liver Disease
Individuals with non-alcoholic fatty liver disease (NAFLD) may particularly benefit from retatrutide's glucagon-mediated hepatic fat reduction, which showed up to 81% liver fat reduction in trials.
What to Expect with Retatrutide
Retatrutide is administered as a once-weekly subcutaneous injection. Treatment begins with a low dose that is gradually titrated upward over several weeks to minimize gastrointestinal side effects and allow your body to adjust. Most patients reach their target maintenance dose within 4 to 8 weeks of starting treatment.
Patients typically begin noticing appetite suppression within the first one to two weeks. Measurable weight loss usually becomes apparent by weeks 3 to 4, with the rate of loss accelerating as the dose is increased. Based on Phase 2 trial data, patients can expect continued progressive weight loss over 48 or more weeks of treatment. Our providers monitor your progress with regular check-ins, lab work, and body composition assessments to ensure optimal dosing and safety throughout your protocol.
At Rewind Anti-Aging of Miami, we combine retatrutide with nutritional guidance and lifestyle optimization to maximize results and build sustainable habits that support long-term weight maintenance.
Weeks 1-4: Titration Phase
Low starting dose with gradual increases. Appetite reduction begins. Minor GI adjustment period for some patients.
Weeks 4-12: Active Weight Loss
Target dose reached. Significant appetite suppression, measurable weight loss, and improved metabolic markers. Regular monitoring and dose adjustments as needed.
Weeks 12-48+: Progressive Results
Continued steady weight loss toward goal. Ongoing provider check-ins, lab monitoring, and protocol refinement. Body composition improvements become increasingly visible.
Side Effects of Retatrutide
Like other GLP-1 class medications, retatrutide's most common side effects are gastrointestinal. These are generally mild to moderate and tend to improve as treatment continues.
Nausea
The most commonly reported side effect, particularly during dose escalation. Usually mild and diminishes as the body adjusts. Eating smaller meals and avoiding high-fat foods can help.
Diarrhea
Loose stools may occur in some patients, especially in early weeks. Typically resolves without intervention as the GI system adapts to the medication.
Vomiting
Less common than nausea. When present, it is usually associated with dose increases and resolves quickly. Slow titration is the key strategy for prevention.
Constipation
Some patients experience reduced bowel frequency due to slowed gastric emptying. Adequate hydration and fiber intake are recommended.
Decreased appetite
While reduced appetite is the primary therapeutic mechanism, some patients may experience appetite suppression beyond what is comfortable. Dose adjustment can address this.
All patients are closely monitored throughout treatment. Dose adjustments are made proactively to manage side effects while maintaining therapeutic efficacy.
Related Treatments
Semaglutide Therapy
GLP-1 receptor agonist for medical weight loss, appetite suppression, and metabolic health improvement.
Learn more →Tirzepatide Therapy
Dual-agonist GLP-1/GIP peptide for powerful weight loss with clinical results up to 22.5% body weight reduction.
Learn more →Tesofensine Therapy
Neurotransmitter reuptake inhibitor that reduces appetite and increases metabolic rate for weight loss.
Learn more →Explore Retatrutide in Depth
Retatrutide vs Semaglutide: Comparing Weight Loss Peptides
How the triple-agonist retatrutide stacks up against the GLP-1-only approach of semaglutide.
Retatrutide Dosage Guide: What to Know
Understanding retatrutide dosing, titration schedules, and how to optimize your protocol.
How Does Retatrutide Work? The Science Explained
A deep dive into the triple-agonist mechanism and why it produces superior results.
Frequently Asked Questions About Retatrutide
What makes retatrutide different from semaglutide or tirzepatide?
Retatrutide is a triple-agonist peptide that activates three receptors simultaneously: GLP-1, GIP, and glucagon. Semaglutide targets only GLP-1, while tirzepatide targets GLP-1 and GIP. The addition of the glucagon receptor is what sets retatrutide apart — glucagon receptor activation increases energy expenditure, promotes fat oxidation, and enhances hepatic lipid metabolism. In Phase 2 trials, this triple mechanism produced weight loss of up to 24.2% of body weight at 48 weeks, surpassing results seen with semaglutide and tirzepatide in comparable timeframes.
How much weight can I lose with retatrutide?
In the Phase 2 clinical trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide (12mg weekly) lost an average of 24.2% of their body weight over 48 weeks. That translates to roughly 58 pounds for a 240-pound individual. Individual results vary based on starting weight, metabolic factors, dosing, and adherence to dietary and lifestyle modifications.
Is retatrutide FDA approved?
Retatrutide is not yet FDA approved. It is currently in Phase 3 clinical trials being conducted by Eli Lilly. However, compounded versions of retatrutide are available through licensed compounding pharmacies under medical supervision. At Rewind Anti-Aging of Miami, we source all peptides from licensed 503B compounding pharmacies that meet USP quality standards.
What are the common side effects of retatrutide?
The most common side effects are gastrointestinal in nature — nausea, diarrhea, vomiting, and constipation. These are similar to other GLP-1-class medications and tend to be most pronounced during the initial dose titration phase. Most patients find that side effects diminish significantly after the first few weeks as the body adjusts. Slow, gradual dose escalation is the primary strategy for minimizing GI discomfort.
How is retatrutide administered?
Retatrutide is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection is given with a small insulin-type syringe and most patients find it quick and relatively painless. Dosing starts low and is gradually increased over several weeks to minimize side effects and allow the body to adjust.
Can retatrutide be combined with other weight loss treatments?
Yes. Retatrutide can be part of a comprehensive weight management protocol that may include metabolic support, nutritional guidance, and other therapies. At Rewind Anti-Aging of Miami, our providers design individualized treatment plans based on your metabolic profile, body composition, and health goals. We evaluate each patient to determine whether retatrutide alone or a combination approach is optimal.
Start Your Weight Loss Journey with Retatrutide
Retatrutide represents the next frontier in medical weight loss. Schedule a consultation to find out if this triple-agonist peptide is right for your goals.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PubMed
⚕ Medical Disclaimer
The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All treatments at Rewind Anti-Aging of Miami are performed under the supervision of licensed medical professionals. Individual results may vary. Consult your physician before beginning any new treatment protocol.
Meet our clinical team →Areas We Serve in Miami & South Florida
Our Wynwood clinic at 24 NW 29th Street serves patients across the Miami metro in person and the entire state of Florida via telehealth.